Drug news
Rigel Pharma corrects information concerning PDUFA date for fostamatinib for adult patients with chronic immune thrombocytopenia.
Rigel Pharmaceuticals, Inc. reported that due to an error by the external host of its investor relations website, inaccurate information was displayed regarding the FDA review of the New Drug Application (NDA) for fostamatinib for the treatment of adult patients with chronic immune thrombocytopenia (ITP). The website has been corrected. The FDA is continuing its review of the NDA and the Prescription Drug User Fee Act (PDUFA) action date is April 17, 2018.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.